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Background: Colorectal cancer (CRC) is one of the most common malignancies 
worldwide, and a substantial group of patients will develop metastases. Survival for 
metastatic CRC (mCRC) has improved, but mainly for trial patients. Precision 
medicine is essential to improve survival and avoid overtreatment. Studies of 
prognostic and predictive markers for mCRC patients are mainly based on highly 
selected patients in clinical trial cohorts. 
Objective: We aimed to report real-world data on the incidence and impact of 
predictive and prognostic tumour biomarkers in a prospectively collected 
Scandinavian population-based cohort of mCRC patients. 
Methods: Immunohistochemistry and DNA sequencing of tumour biomarkers was 
performed. 
Results: The incidence of tumour microsatellite instability (MSI) and BRAF mutation 
(BRAFmut) was 7 % and 20 %, and both markers were associated with poor patient 
outcome. MSI was associated with BRAFmut and patient age, indicated poor response 
to 1st-line chemotherapy, and few patients received 2nd-line treatment.  
Loss of CDX2 expression was identified in a subgroup of tumours, defining patients 
with poor prognosis and indicated inferior chemotherapy benefit. CDX2 loss defined 
new prognostic subgroups in BRAFmut and KRAS mutated cases, respectively. 
In chemotherapy-treated patients, a high density of tumour infiltrating CD3 
lymphocytes and CD68 macrophages were independent good prognostic markers for 
overall survival. MSI was an independent poor prognostic marker despite high 
immunogenicity.  
Conclusions and consequences: We found a higher frequency of MSI and BRAFmut in 
this population-based mCRC cohort than previously reported. Patients with MSI 
tumours were much older and most harboured tumour BRAFmut, in strong contrast to 
patients in recent clinical trial cohorts. Furthermore, CDX2 status and immune 
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1.1 epidemiology and aetiology 
Colorectal cancer (CRC) is ranked as the fourth leading cancer disease worldwide and 
the third leading cause of cancer-related death, with the highest incidence among 
Western and high-income countries. Globally there were 1.9 million estimated new 
cases and 0.9 million deaths in 2020 (1)  
 
Figure 1 Estimated age-standardised incidence of colorectal cancer worldwide in 2020. Available 
from: https://gco.iarc.fr/today, accessed [13 03 2021](2). 
 
In Scandinavia, CRC is the second most common cancer disease in men and women 
(3). The age-standardised incidence rate for men in 2018 was 82.5 in Norway and 76.2 
in Denmark, and higher than what is observed in Sweden (56.2) (Figure 2) (3). CRC is 
generally a disease of the elderly population with a median age of around 70 years (4). 
Due to increased life expectancy and change in lifestyle, CRC incidence is still rising 
in many countries. In Norway, the incidence rate has nearly doubled since the 1970s, 
is steadily increasing, and now displays the highest incidence in Scandinavia. A less 
steep increase is seen in Denmark, and a relatively flat incidence curve is observed in 




increase in Norway is not known, but obesity, dietary factors and gene pool 
vulnerability to environmental changes and lifestyle factors have been suggested. A 
substantial increase in the incidence among younger patients (<50 years) was recently 
reported in a study of seven high-income countries (5). A significant proportion of 
CRC patients have metastatic disease, approximately 25% of patients present with 
metastatic CRC (mCRC) at diagnosis, and another 20% will eventually develop 
metastasis (4).  




Figure 2 Trends in age-standardised incidence and mortality rates for colorectal cancer patients in 





Several risk factors have been identified, causing epigenetic and genetic changes in 
colorectal epithelial cells, eventually developing into cancer. The epithelium displays 
the highest cell division (mitotic turnover) in the human body. Due to age-related 
changes such as stem cell senescence, genome instability, accumulation of mutations, 
telomere attrition and epigenetic alterations, age is considered the leading risk factor 
for epithelial cancers (6). Different lifestyle characteristics have also been linked to 
increased risk, such as a diet rich in red or processed meat, obesity, excessive alcohol 
consumption, smoking and reduced physical activity (7, 8). Changes in these lifestyle 
factors have been estimated as the most important preventive measures for CRC 
development (8, 9). Long-term use of aspirin (acetylsalicylic acid), a non-steroidal 
anti-inflammatory drug, has also been associated with reduced CRC incidence (10, 
11). Several studies suggest that the gut microbiome plays a role in CRC development 
(12, 13) as intestinal dysbiosis and increased colonisation of specific microbes in 
intestinal mucosa and tumour tissue of CRC patients has been observed. However, 
factors that predispose to CRC, such as diet, physical activity and obesity, could alter 
the gut microbiome, and it is not clarified if the altered microbiome is a cause or a 
consequence of CRC development (14). Chronic inflammation is a well-established 
risk factor for cancer development, and an increased risk for CRC is observed in 
patients with chronic mucosal inflammation conditions such as ulcerative colitis (15). 
Around 20-30% of CRC occur in first- or second-degree relatives, indicating a 
hereditary component. However, only around 5% of cases are identified as hereditary 
cancer syndromes with known germline mutations (16). The two main cancer 
syndromes are hereditary nonpolyposis colorectal cancer (HNPCC), also termed 
Lynch Syndrome, and familial adenomatous polyposis (FAP). Most HNPPC cases 
present heterozygous genetic mutation in one of the DNA mismatch repair (MMR) 
genes, and in FAP, heterozygous mutation is found in the tumour suppressor gene 
(TSG) adenomatous polyposis coli (APC).  




1.2.1 Diagnosis and staging 
The most commonly reported symptoms at diagnosis of CRC is faecal bleeding, 
abdominal pain and change in bowel habits (17). However, many patients report no 
symptoms, and if present, it often occurs late in the disease course. The transformation 
of precancerous lesions to CRC takes many years, and early detection is essential for 
curation. For these reasons, different screening programs, such as faecal blood tests, 
sigmoidoscopy and colonoscopy, of the healthy population above 50 years has been 
implicated in many countries. In European countries with long-standing screening 
programs, CRC incidence decreased over time, and these countries obtained the most 
significant decrease in CRC mortality (18). These findings support the initiation of 
screening programs, particularly in high-incidence countries such as Norway. A CRC 
screening pilot in Norway was recently published (19), and the health authorities have 
decided to initiate a national screening program for people above 55 years in 2021. In 
Denmark, a CRC national screening program was initiated in 2014.  
Colonoscopy and proctoscopy with tumour biopsy are standard diagnostic procedures 
for colorectal cancer. Other imaging methods such as computer tomography (CT) and 
Magnetic resonance imaging (MRI) are also implemented for preoperative 
evaluation/investigation, staging the disease, and identifying metastatic spread. 
Histopathological staging of the tumour is performed after surgical resection. The most 
commonly used system for staging CRC is the TNM system for solid tumours, 
regularly updated by the Union for International Cancer Control (UICC) (Table 1) 
(20). According to the American Joint Committee on Cancer (AJCC) staging system, 
the TNM classification is further used to categorise CRC into four stages. Stage I-III 
represent localised tumour according to T and N status, and stage IV is the presence of 
distant metastases (Table 2). Prognosis is strongly associated with this staging system, 
with a poorer prognosis with increasing stage due to a higher risk of metastases. 
Estimated 5-year relative survival for male colon and rectal cancer patients in Norway 
diagnosed in 2015-2019 is 98.3 for stage I-II, 84.4 % for stage III and 15.5 % for stage 




usually fatal. Staging is therefore essential for prognostic assessment and is used to 
guide treatment strategies for each patient.  
Table 1 The Union for International Cancer Control (UICC) TNM classification of malignant 
tumours, colorectal cancer, eight edition (20) 
T – Primary Tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: invasion of lamina propria 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades subserosa or into non-peritonealised pericolic or perirectal tissues 
T4a Tumour perforates visceral peritoneum 
T4b Tumour directly invades other organs or structures 
N – Regional Lymph Nodes 
NX  Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1a Metastasis in 1 regional lymph node 
N1b Metastasis in 2 to 3 regional lymph nodes 
N1c Tumour deposit(s), i.e. satellites, in the subserosa, or in non-peritonealised pericolic or 
perirectal soft tissue without regional lymph node metastasis 
N2a Metastasis in 4–6 regional lymph nodes 
N2b Metastasis in 7 or more regional lymph nodes 
M – Distant Metastasis 
M1a Metastasis confined to one organ (liver, lung, ovary, non-regional lymph node(s)) without 
peritoneal metastases 
M1b Metastasis in more than one organ 
M1c Metastasis to the peritoneum with or without other organ involvement 
 
Table 2 American Joint Committee on Cancer staging of colorectal cancer according to the UICC 
TNM classification of malignant tumours, eight edition (20) 
AJCC staging TNM 
Stage I  T1, T2 N0 M0 
Stage II  T3, T4 N0 M0 
Stage III  Any T N1, N2 M0 
Stage IV  Any T Any N M1 
 
1.2.2 Histopathological evaluation 
Adenocarcinoma is the most commonly identified phenotype in colorectal cancer. 
Adenocarcinomas are further graded according to differentiation from grade I-III. 
Grade I refer to highly differentiated tumours, and grade III poorly differentiated 
tumours. A high tumour grade is associated with a poor prognosis. Some of these 
tumours produce mucin, and others are composed of signet ring cells. Tumour 
budding, extramural venous invasion (EMVI) and perineural infiltration has also been 
21       
 
 
associated with poor prognosis and is recommended to be included in the pathology 
report (21). 
1.3 Prognosis  
The prognosis for CRC patients has greatly improved in the last decades, and 5-year 
overall survival (OS) is around 66% in Scandinavia (Figure 3). The observed 
improved prognosis is probably due to earlier and enhanced detection methods, 
improved surgical treatment, chemoradiation for localised rectal cancer and adjuvant 
chemotherapy for locoregional disease. Improved prognosis is also observed for 
mCRC patients due to development in systemic treatment options, personalised 
treatment approach, and a more aggressive surgical approach if resectable metastases. 
In 2010-2015 the 5-year OS for mCRC patients in Norway was 16% and 20% for 
colon and rectal cancer, respectively, compared to 5% and 4% in 1980-1984 (4). The 
large majority of patients with metastatic disease cannot be cured, illustrated by a 
median survival of 20-30 months and five-year survival of 9-19% in study patients 
(22, 23). However, median OS is only 15 months for chemotherapy-treated patients in 
population-based cohorts (24, 25), and an even more grim prognosis is reported in 






Figure 3 Trends in 5-year age-standardised relative survival for colorectal cancer patients in 
Scandinavia. Available from: https://nordcan.iarc.fr/, accessed [13 03 2021] 





1.4.1 Localised CRC 
In localised CRC without metastases, surgical resection of the primary tumour with 
sufficient margins is mandatory for curating the disease. The addition of chemo- or 
radiotherapy before (neoadjuvant) or following (adjuvant) surgery is based on specific 
risk factors for recurrence and survival (27). In colon cancer with lymph node 
metastases (stage III) or high-risk stage II, adjuvant chemotherapy with fluorouracil 
(5-FU)/folinic acid (FA) or capecitabine with oxaliplatin (FOLFOX or CAPOX) for 3-
6 months is recommended to improve disease-free survival (DFS) and OS for these 
patients. For rectal cancer, neoadjuvant radiotherapy (5Gy x 5) followed by 
chemotherapy (FOLFOX or CAPOX) is recommended if the tumour is classified as T4 
or N2, presence of extramural venous invasion, tumour or pathological lymph node is 
located close to (< 1mm) or outside the mesorectal fascia. However, preoperative long-
term chemoradiation is recommended for very locally advanced tumours. In the case 
of tumour perforation or insufficient resection margins obtained during surgery, 
adjuvant chemoradiotherapy is recommended for previously untreated patients. The 
use of adjuvant chemotherapy for rectal cancer is debated internationally and generally 
not recommended in Norway but might be considered if risk factors are identified after 
surgery (27). 
1.4.2 Metastatic colorectal cancer 
The most frequent location of synchronous mCRC is liver (74%) or peritoneum (23%) 
(28). In a metachronous setting, liver (60%), lung (39%), lymph nodes (22%) or 
peritoneum (19%) are the most commonly affected sites (29).  
Metastatic surgery 
The main treatment option for most mCRC patients is systemic treatment with 
palliative intent, although some patients have a possible curative option with 
metastasectomy if resectable single organ metastasis to liver, lung or peritoneum. 




The effect of perioperative or adjuvant chemotherapy after metastasectomy is not 
clarified. In Norway, around 20% of mCRC patients with liver metastases undergo 
liver resection, with a 4-year OS of 55 % compared to 9 % in the unresected group 
(30), but unfortunately, the majority relapse (31, 32). Pulmonary resection is less 
frequent and, in a Danish study, only performed in 28 of 736 cases with solitary 
pulmonary metastases (33). If the patient is considered inoperable due to poor 
performance status or technical reasons, radiofrequency ablation or stereotactic 
radiation could be an option in the case of minor and limited lung or liver metastases. 
Maximal cytoreductive surgery followed by hyperthermal intraperitoneal 
chemotherapy (CRS HIPEC) is recommended for selected patients with resectable 
peritoneal metastases (34). This treatment method has shown 40 % 5-year OS in this 
poor prognostic group (35). The method consists of surgical removal of all 
macroscopic tumours, followed by intraperitoneal heated chemotherapy 
administration, attempted to kill remaining cancer cells. 
Systemic treatment 
Chemotherapy is the major backbone of systemic treatment (Figure 4), although the 
response and survival benefits are limited. The two main chemotherapy treatment 
options are combination treatment of 5-FU/FA with oxaliplatin (FOLFOX) or 
irinotecan (FOLFIRI). The response and survival benefit of these regimens are 
considered equally efficient, with a 20-30 % increased overall response rate (ORR) 
and 2-3 months increased progression-free survival (PFS) and OS compared to 5-
FU/FA alone (36, 37). A higher RR and survival are obtained with combined targeted 
antibody treatment; epidermal growth factor receptor (EGFR) inhibitor (cetuximab or 
panitumumab), or vascular endothelial growth factor (VEGFR) inhibitor 
(bevacizumab). EGFR inhibitors bind to the EGFR receptor on the surface of tumour 
cells and other human body cells, blocking the signalling cascade of the RAS-RAF-
MAPK pathway, otherwise leading to cell growth and proliferation. Patients with 
tumour Rat Sarcoma viral oncogene homologue mutations (RASmut) have no survival 
benefit from EGFR-inhibitors due to constant signalling through the RAS-RAF-
MAPK pathway. For RAS wildtype patients, the addition of EGFR inhibitors has 
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shown 10-20 % increased RR, one-two months increased PFS and around five months 
increase in OS compared to FOLFOX or FOLFIRI alone (38, 39). VEGFR inhibitor 
binds to VEGF, secreted by several cells of the human body, including endothelial 
cells and cancer cells. VEGF induces the development of blood vessels (angiogenesis), 
important for tumour development and progression. The addition of the VEGFR-
inhibitor bevacizumab has shown around 10 % improvement in RR and 1-4 months 
improved PFS and OS compared to combination chemotherapy alone (40, 41). 
Studies of oral fluoropyrimidine TAS-102 (Lonsurf) and a multikinase inhibitor 
regorafenib have shown survival benefit in 3rd line setting. Due to marginal survival 
benefit and a high toxicity profile, it is considered the last treatment option for selected 
patients with good performance status.  
Patients with tumour B-raf proto-oncogene mutation (BRAFmut) have a poor 
prognosis with often rapidly progressive disease. These patients are often 
recommended intensified 1st-line chemotherapy with triplet chemotherapy regimen 
FOLFOXIRI plus bevacizumab if considered eligible for this intensive treatment with 
a high toxicity profile (42, 43). Recently 2nd-line treatment with BRAF inhibitor 
(encorafenib) combined with EGFR inhibitors has shown promising results in patients 
with BRAFmut tumours (44). This treatment is now approved as 2nd-line treatment by 
the USA Food and Drug Administration (FDA) and European Medicines Agency 
(EMA). Reimbursement is approved by the health authorities in Denmark but currently 
under consideration at New Health Technologies (Nye Metoder) in Norway (45). 
A major breakthrough in cancer treatment was achieved by developing immune 
checkpoint inhibitors (ICIs), inhibiting the negative regulation of immune cells. For 
mCRC patients, durable response and survival benefit of programmed death 1 (PD-1) 
ICIs (pembrolizumab and nivolumab) have been obtained in patients with tumour 
microsatellite instability (MSI) status (46, 47). This was recently validated in a 
randomised 1st-line study of pembrolizumab vs investigators choice of standard 
chemotherapy, with median PFS 16.5 vs 8.2 months and ORR 44 % vs 33 % (48). 




mCRC patients with MSI tumours, and reimbursement is under consideration at New 
Health Technologies in Norway.  
 
Figure 4 Recommended treatment algorithm for metastatic colorectal cancer patients. Figure from the 
Norwegian national guidelines for the treatment of colon and rectal cancer, modified with permission 
from the author (27)  
 
1.5 Population-based cohort studies 
Studies on population-based cohorts are essential to understand the biology and 
prognosis of the patients that we meet in the clinic. However, most biomarker studies 
are based on trial patient cohorts, and these patients are highly selected compared to 
the general mCRC patients. In our Scandinavian population-based cohort, patients 
included in trials were significantly younger, had better performance status, less often 
peritoneal metastases and abnormal blood tests (haemoglobin, white blood cell count, 
ALP and LD) (49). As the majority of mCRC patients are not represented in clinical 
trials, there is a risk that the trial results will not replicate in the clinical practice. In 
recent mCRC trials, median survival has reached up to 30 months, compared to 10-15 
months in population-based cohorts (24, 26). Previous biomarker studies have revealed 
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few cases with specific tumour molecular alterations. But due to the inferior survival 
in population-based cohorts, there is reason to believe that poor prognostic markers 
would be more frequent in unselected cohorts. We have previously demonstrated a 
higher frequency of BRAFmut in our cohort (25), and we hypothesize that other poor 
prognostic markers would also be more frequent. There is a need for predictive and 
prognostic markers validated in population-based cohorts to guide treatment selection 
and improve mCRC patients' survival. 
 
Figure 5 Most biomarker studies are based on trial patient cohorts, but the selected patients in clinical 
trials might not represent the general patient population.   
 
With a median age of 70 years at diagnosis, mCRC is generally a disease of the 
elderly. However, little is known about the optimal treatment of elderly patients, as 
they are usually not included in clinical trials. Elderly patients have more 
comorbidities and could have functional and organ decline with increased risk of side 




receipt is inversely associated with age (26). However, elderly patients today are more 
fit and eager to receive chemotherapy (50). The selection of elderly patients that may 
profit from treatment without risking too much toxicity and which treatment to choose 
for each patient is an everyday challenge for clinicians. Population-based cohorts are 
therefore ideal for studying this large subgroup of mCRC patients.   
1.6 Molecular characteristics of CRC 
Both gene defects and epigenetic changes are involved in tumour development. Gene 
defects have been identified as causes of inherited CRC syndromes, including APC 
gene alterations in FAP and defects in the DNA MMR system in HNPCC. In sporadic 
CRC, alterations in these and other genes accumulate in a somatic lineage during life. 
Such alterations include point mutations, amplifications, insertions or deletions of 
DNA sequence stretches. Three classes of genes are affected in the malignant cells; 
tumor suppressor genes and repair genes often need to be in a loss of function state to 
exert a selection advantage to the tumor cells, whereas protooncogenes will be become 
active oncogenes through increased expression, typically by mutation, 
gain/amplification or chromosomal translocation.  
Epigenetics has a vital role in preserving genomic instability, embryonic development 
and tissue differentiation. The epigenetic machinery controls gene expression by 
attaching or removing chemical groups (mainly methyl, phosphor and acetyl-groups) 
to DNA, chromatin and histones, causing modification and accessibility of DNA 
structure. Factors influencing epigenetic regulation are diet, chemicals, age, bacteria, 
although some traits are inheritable (6). 
The Adenoma-Carcinoma sequence 
Adenomatous polyps (adenomas) are identified as precursor lesions to CRC that 
develop from glandular epithelium. They display dysplastic morphology and altered 
differentiation compared to polyps or normal colonic epithelium. However, only a 
fraction of adenomas eventually develop into adenocarcinoma, and the progression is 
thought to take many years (51). Accumulation of multiple genetic and epigenetic 
events is required for CRC development by an evolutionary process termed clonal 
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selection. This multistep genetic model of colorectal carcinogenesis is proposed with 
mutation of the TSG APC occurring as an early event, followed by Kirsten Rat 
Sarcoma viral oncogene homologue (KRAS) mutation (KRASmut) and subsequent 
inactivation of the TSG Tumour Protein 53 (TP53) (52). Genes that control cell 
survival, cell fate and genome stability are referred to as driver genes. At least 2-3 
driver gene mutations are needed for a normal cell to differentiate into a cancer cell 
(6). Each individual tumour contains numerous mutations, with only a handful of 
driver gene mutations, and the majority classified as passenger mutations (53). The 
most common driver gene mutations in CRC are APC, KRAS, BRAF, PIK3CA, 
SMAD4 and TP53.  
It was later identified that not only adenomas but also serrated polyps could develop 
into adenocarcinoma through an alternative pathway (CIMP). In general, three distinct 
pathways for CRC development have been identified: 1) mutations in DNA mismatch 
repair leading to microsatellite instable (MSI) phenotype, 2) mutations in APC/Wnt 
pathway characterised by Chromosomal instability (CIN) phenotype and 3) genome 
hypermethylation in CpG island methylator (CIMP) phenotype (figure 6). These 






Figure 6 Pathways leading to colorectal cancer development, reprint from East 2017 (55) with 
permission. 
 
1.6.1 Microsatellite instability  
Microsatellites are short repetitive DNA sequences flanked by unique sequences, 
scattered throughout the genome, and prone to high mutation rates when replicated. 
The DNA mismatch repair (MMR) complex's role is to identify and repair DNA 
replication errors. This complex consists of several genes, the essential being: MLH1, 
MSH2, MSH6 and PMS1/2. The MMR system is well conserved from the bacterial 
MutS,L,H system to humans. Among the human homologs of MutS, a heterodimer of 
MSH2 with MSH6 or MSH3 recognizes mismatches and small insertions or deletions. 
The homologs of MutL make a heterodimer of MLH1 with PMS2, PMS1 or MLH3, 
acting as endonucleases after complexing with MutS. Genetic or epigenetic 
inactivation of MMR genes, termed deficient MMR (dMMR), results in microsatellite 
instability (MSI) (56). A tumour demonstrating MSI in ≥ 30 % mononucleotide or 
dinucleotide repeats are termed MSI high (57). CRCs with dMMR/MSI are 
hypermutated with >10 mutations/Mb (58). They typically acquire somatic mutations 
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in short repetitive sequences, frequently found in TSG. Protooncogenes and TSG with 
repetitive sequences are the major somatic mutations in these tumours (54). MSI-
induced frameshift mutations lead to a significant amount of neoantigens that make 
MSI tumours more immunogenic with increased amounts of tumour infiltrating 
lymphocytes (TILs) compared to Microsatellite stable (MSS) tumours. MSI tumours 
are more often located in the proximal colon, poorly differentiated, with mucinous or 
signet ring histological type (56).  
HNPCC is identified as the cause of 2-4 % of localised CRC. These patients present an 
autosomal dominant inheritance of CRC caused by germline mutations in one of the 
four MMR genes or the epithelial adhesion molecule (EPCAM) gene, leading to 
transcriptional inactivation of MSH2. Some families have also been identified with 
heritable MLH1 or MSH2 promoter methylation. Patients with HNPCC often develop 
several tumours at an early age, including colorectal, ovarian, endometrium and 
stomach cancer, amongst others (56). Alterations of the microsatellite sequence are 
seen at many loci across the genome in all tumours. Sporadic MSI tumours occur in 
around 15 % of localised CRC (54, 59) and are generally caused by epigenetic loss of 
MLH1 gene expression by promoter hypermethylation through the CIMP pathway 
(discussed later). It often coexists with the gain of BRAFmut, and the presence of 
BRAFmut generally rules out an inherited cause. Patients diagnosed with MSI and 
BRAF wildtype (BRAFwt) CRC are recommended to proceed with genetic screening 
with blood-based germline mutation analysis for HNPCC (60). 
1.6.2 Chromosomal instability 
Chromosomal instability (CIN) tumours develop through the classical adenoma-
carcinoma sequence and are present in 70-85 % of CRC (61, 62). They are 
characterised by an imbalance in chromosome number and loss of heterozygosity. 
Mutations in several genes that drive chromosome alterations have been proposed as 
potential mechanisms of CIN (62). The resulting alterations in chromosome 
segregation, telomere dysfunction and DNA damage response leads to mutations in 
specific oncogenes and TSG such as APC, KRAS, PIK3CA and TP53 (61). APC 




1.6.3 CpG island methylator phenotype, the serrated pathway 
CpG-islands are regions in the genome rich in CpG dinucleotides often seen in 
promoter regions of genes. More than 50 % of human genes are epigenetically 
regulated by methylation at CpG-islands, leading to silencing of gene expression. CpG 
island methylator phenotype (CIMP) tumours are hypermethylated at many different 
CpG-islands resulting in epigenetic instability and inactivation of TSG. They are 
believed to represent around 20 % of all CRC (62) and present a distinct histological 
phenotype, apparent already in early lesions, termed Sessile serrated adenomas (55). 
They are more often observed in patients with right-sided primary tumour location, 
more advanced tumour stage, female gender and older age and has also been 
associated with a poor prognosis (63). There is considerable overlap with the MSI 
pathway as they often display methylated promoter CpG island of MLH1, which 
accounts for most sporadic MSI (62, 64). They often have co-occurring BRAFmut and 
promoter methylation induced loss of the TSG caudal-type homeobox 2 (CDX2) (55, 
65).  
1.6.4 Oncogenes and tumour suppressor genes 
The RAS proteins control several signalling pathways within the cell (66). In response 
to extracellular growth factors binding to endothelial growth factor receptors (EGFR), 
they regulate multiple cellular functions, such as proliferation, apoptosis and 
angiogenesis (Figure 7). RAS proteins belong to the family of small GTP binding 
proteins (GTPases). In the inactive state they bind GDP. Upon activation, GDP is 
phosphorylated to GTP, changing the conformation of the RAS protein. Mutated RAS 
remains active, leading to continuous signalling in downstream pathways 
(Ras/Raf/MAP/MEK/ERK and PI3K) (Figure 6). The subgroups of the RAS protein 
family consist of KRAS, Neuroblastoma rat sarcoma viral oncogene homolog (NRAS) 
and Harvey rat sarcoma viral oncogene homolog (HRAS). KRASmut is the most 
common RAS mutation and has been identified as an early event in CRC development 
and is found in 40-50 % in mCRC (25, 38, 67). The most frequent location of 
KRASmut is point substitutions in exon two codons 12 and 13 and less common at 
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exon three and four. The frequency of NRAS mutation (NRASmut) in mCRC is 3-7 % 
(38, 68, 69).  
 
Figure 7 The RAS signalling pathway is activated by growth factors binding to endothelial growth 
factor receptors on the cell surface, leading to GTP binding and conformation of RAS to its active 
state and subsequent signalling in downstream pathways. Reprint from (61) with permission 
 
The BRAF proto-oncogene belongs to the RAF family of serine/threonine protein 
kinases. BRAF proteins are activated by RAS in the EGFR-mediated RAS pathway. 
They regulate the Mitogen-activated protein kinase (MAPK) pathway, activating 
MAPK effectors MEK and ERK, leading to cell growth, proliferation, differentiation, 
migration, apoptosis and survival (70). BRAFmut is frequently found in human 
cancers, especially malignant melanoma, thyroid, ovarian and colorectal cancer. The 
most common BRAFmut is V600E BRAF with T>A transversion at position 1799 of 
exon 15, resulting in the substitution of Valine by Glutamate at position 600 (70, 71). 
This resembles the phosphorylation needed for BRAF activity, leading to continuous 




with right-sided tumours, female sex, older age, and sporadic MSI. BRAFV600Emut and 
KRASmut are mutually exclusive. Non-V600E mutations have been identified in 
approximately 2 % of mCRC (73, 74). These have a distinct clinical subtype 
associated with left-sided primary tumour location and fewer peritoneal metastases and 
are not associated with MSI, as compared to BRAFV600Emut (73, 75). 
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alfa (PIK3CA) 
protooncogene is a kinase in the PI3K/AKT1/MTOR pathway, located downstream of 
the RAS signalling pathway, regulating cell proliferation, survival and motility(6). 
Mutations lead to continuous activation and signalling and occur in approximately 15-
20 % of CRC (76).  
TP53 TSG is the main cell cycle checkpoint, halting the cell cycle in response to DNA 
damage and initiate repair or apoptosis (77). Loss of function allows excessive 
proliferation and mutations. TP53 mutation is common in many cancers and occurs in 
nearly 60 % of CRC (78) and > 70 % in liver metastases from CRC (79) and plays an 
essential role in the classical adenoma to carcinoma sequence.  
The adenomatous polyposis coli (APC) gene is a TSG and is the most frequently 
mutated gene in sporadic CRC. It is considered a gatekeeping mutation of CRC, 
present in 70-80 % of carcinomas (6). It is found in small benign adenomas and 
dysplastic epithelium, suggesting an early event in the development of most adenomas. 
Germ-line mutations in APC is also identified in some hereditary syndromes (FAP, 
Turcot and Gardner) (54). APC is thought to regulate cell-cell adhesion, migration, 
chromosomal segregation and apoptosis in the colonic crypt. It binds and regulates β-
catenin, inhibiting the β-catenin-dependent Wnt signalling pathway. If APC is 
inactivated, β-catenin accumulates in the cytoplasm and translocate to the nucleus, 
activating many different genes leading to proliferation, differentiation, migration and 
adhesion of colorectal cells (54). Together with TGF-β, β-catenin induces epithelial-
mesenchymal transition (EMT) (6), which is important for cancer progression and 
metastasis.   
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The POLE gene encodes the catalytic subunit of DNA polymerase epsilon, one of the 
main DNA replication enzymes. Germline mutation is identified in polymerase 
proofreading associated polyposis. Somatic POLE mutations give rise to an 
ultramutable tumour (62). POLE mutation is an uncommon event in CRC, identified 
only in 1-2 % of cases (80). As for MSI/Lynch syndrome CRC patients, tumour POLE 
mutation is associated with younger age at diagnosis, right-sided primary tumour and 
increased TILs, and improved prognosis in early-stage (80). Despite similar 
clinicopathological characteristics to MSI tumours, they are generally identified as 
MSS (62).   
Human epidermal growth factor 2 (HER2) oncogene, also known as ERBB2, encodes a 
transmembrane glycoprotein receptor and is a member of the EGFR family. Upon 
activation, it stimulates signal transduction through the RAS mediated pathway(81). In 
CRC, the prevalence of overexpression is only around 2 %, and the prognostic effect is 
not clarified (82, 83). Mutations in HER2 occurs in 2-6 % (84, 85) in CRC. These 
mutations are believed to be activating mutations, further stimulating the RAS 
signalling pathway. 
Caudal-type homeobox 2 (CDX2) is an intestine-specific transcription factor and 
function as a master gene regulator of gene expression in intestinal epithelial cells, 
regulating cell differentiation, proliferation, adhesion, and migration. It is essential for 
intestinal embryonal development and the homeostasis of the continuously renewing 
mature intestinal epithelium. The protein expression of CDX2 is considered one of the 
most sensitive and specific intestinal differentiation markers (86). Loss of CDX2 
expression causes changes in the mucosal architecture leading to developmental 
disorders and is believed to be involved in intestinal inflammation such as 
inflammatory bowel disease (87). There is also increasing evidence that CDX2 play a 
tumour suppressive role in carcinogenesis. Studies of heterozygous CDX2 mice 
developed multiple colonic polyps with an increased risk of tumour development (88). 
A recent study demonstrated that CDX2 inhibited EMT and the development of liver 
metastases of CRC (89). Loss of CDX2 expression is identified in a subset of CRC, 




rarely caused by a mutation in the CDX2 gene but rather as a consequence of promoter 
methylation. Together with BRAFmut, it is often associated with the serrated (CIMP) 
pathway (65). It has also been associated with MSI, right-sided primary tumour 
location, poor tumour differentiation and advanced tumour stage (90). CDX2 loss has 
been found enriched in consensus molecular subgroup (CMS) 1 and CMS 4 subgroup 
(91, 92).  
1.6.5 Consensus molecular subgroup (CMS) classification 
In 2015 a consensus of molecular subgroups based on gene expression data from the 
primary tumour of 4151 CRC patients was published (93). Four different clusters were 
identified, termed consensus molecular subgroup (CMS) 1-4. However, 13 % of 
patients were defined as mixed or unclassified. The CMS1 (MSI) subgroup was found 
in 14 % of patients and was associated with MSI, CIMP high, hypermutation, 
BRAFmut, immune infiltration, and worse survival after relapse. The CMS2 
(epithelial) subgroup was found in 37 % of patients and was associated with the Wnt 
pathway and MYC activation. The CMS3 (epithelial) subgroup was found in 13 % of 
patients and was associated with mixed MSI status, CIMP low, KRASmut and 
metabolic deregulation. The CMS4 (mesenchymal) subgroup was found in 23 % of 
patients. It was associated with stromal infiltration, TGF-β activation, angiogenesis, 
metastatic disease and worse OS and recurrence-free survival. The development of 
CMS classification was mainly based on analyses of localised CRC patients but has 
later been reported as a potential prognostic classifier in mCRC trial cohorts (94, 95). 
It has also been suggested to stratify treatment response or resistance, but 
standardization of methods on FFPE tumour tissue and prospective clinical trials are 
needed (96, 97). At present, CMS classification has no clinical implication. 
1.7 Cancer development and the immune system 
For centuries, it has been acknowledged that the immune system plays an essential role 
in cancer development and progression in conflicting ways. Tumour-promoting 
inflammation and evasion of immune destruction have been recognised as common 
traits for the cancerous transformation of normal cells and are proposed as important 
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contributors to the “Hallmar s of cancer” (98) (Figure 8). It is well known that some 
tumours are highly infiltrated by immune cells, and some chronic inflammatory 
conditions and viral infections eventually develop into cancer. Inflammation and 
tumour infiltrating immune cells secrete growth factors and other signalling molecules, 
stimulating tumour proliferation, survival, angiogenesis, invasion and metastasis (99, 
100). Although driver gene mutations and genomic- and epigenomic instability are 
essential for the initial tumour formation, microenvironmental stimuli are needed to 
evolve metastasis (99, 101). The immune system is therefore believed to play an 
essential role in tumour development.  
On the contrary, the immune system can recognise and evade tumour cells at an early 
stage (100, 102), a process called immune surveillance. Immune surveillance is 
believed to be the reason for the increased risk of cancer developement in 
immunocompromised individuals and the improved prognosis in patients with highly 
inflamed tumours (103). In the last two decades, the discovery of ICIs that inhibits T 
cells' negative regulation has led to a major breakthrough in cancer treatment and was 





Figure 8 The hallmarks of cancer by Hanahan and Weinberg. Avoiding immune destruction is one of 
the recognised hallmarks, and six of eight hallmarks involve contributions by infiltrating immune 
cells. Reprinted from (104) with permission  
 
1.7.1 Immune cells of the tumour microenvironment 
The human body's immune system consists of different cells that recognize, memorize 
or eradicate foreign cells. Although cancer cells are developed from the host's cells, 
mutations can create neoantigens that are detected by the immune system. TILs 
consists of subsets of T lymphocytes. They are important mediators of the adaptive 
immune system, inducing cell-mediated immunity. The three major groups are CD4 
helper T cells, CD8 cytotoxic T cells (CTLs) and CD4 regulatory T cells (Tregs). 
Activation is dependent on antigen-presenting cells (such as macrophages), presenting 
tumour antigen on major histocompatibility complex (MHC) class II on their cell 
surface, which binds to the T cell receptor (TCR). The TCR is then rearranged to 
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recognize this specific antigen upon binding to MHC class I on tumour cells. All 
nucleated cells express MHC class I on their surface, presenting fragments of any 
protein component within the cell. Upon tumour antigen exposure, CD4 helper T cells 
secrete cytokines that activate other immune cells (lymphocytes and macrophages), 
while CTLs can directly recognize and kill cancer cells. 
On the other hand, Tregs function mainly as inhibitors of the immune response, 
suppressing T cell proliferation and activation. They play an important role in 
preventing the immune system's overactivation and autoimmunity. Other minor 
subgroups of T cells have also been identified, such as Natural Killer (NK) cells. Co-
inhibitory cell surface receptors, such as PD-1 and cytotoxic T-lymphocyte protein 4 
(CTLA-4), are often up-regulated on T-cells after activation (105) (Figure 9). These 
immune checkpoints function as “immunological bra es” b  reducing   cell 
proliferation and cytokine production upon stimulation and is essential to prevent 
autoimmunity and retain immune homeostasis. This is also seen with chronic antigen 
exposure, such as cancer, a process called T cell exhaustion. ICIs blocks co-inhibitory 
receptors (e.g. PD-1, CTLA-4) on T cells and other immune cells or their ligands (e.g. 
PD-L1) on tumour cells or various immune cells, thereby enhancing the anti-tumour 
effect of the immune system. This paradigm shift in cancer treatment has led to an 
impressive survival advantage for many different cancers, but unfortunately, most 







Figure 9 Activation of T cells requires two signals; binding of TCR to MHC and stimulation of co-
stimulatory cell surface receptors. Upon activation and chronic antigen exposure, co-inhibitory cell 
surface receptors (CTLA-4 and PD-1) are up-regulated. Blocking these co-inhibitory signals with 
immune checkpoint blockade (Anti-CTLA4, Anti-PDL-1 or anti-PD-1) enhances the activity of T cells 
and reactivate exhausted T cells. Reprinted from (105) with permission. 
 
Macrophages have a diversity of functions in normal and tumour tissue (106). As part 
of the innate immune system, they recognise and phagocytose pathogens and function 
as antigen-presenting cells for the adaptive immune system. They also secrete 
cytokines and chemokines affecting other immune cells and are essential in regulating 
the immune response and wound healing. A spectrum of macrophages has been 
identified, and the phenotype is determined by stimulation from the surrounding 
microenvironment. The two major groups have antagonising effects; the classically 
activated M1 phenotype with anti-tumour/pro-inflammatory effect and the 
alternatively activated M2 phenotype with pro-tumour/anti-inflammatory effect. It is 
believed that M1 macrophages are the most prominent in the early stage of tumour 
development. However, with tumour progression, M2 activation is induced by the 
secretion of cytokines from other immune cells, stromal cells, and tumour cells (107). 
Many studies have revealed that tumour-associated macrophages (TAMs) resemble the 
M2 phenotype, producing growth factors that stimulate proliferation, angiogenesis and 
survival of cancer cells and suppress infiltration and cytolytic activity of CTLs (107, 
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108) (Figure 10). They also play important parts in the metastatic process by 
remodelling the extracellular matrix components, facilitating tissue invasion (101, 
104).  
 
Figure 10 The effects of tumour-associated macrophages. Reprinted from (108) with permission. 
1.7.2 Immune escape 
Due to immune surveillance, cancer cells must evade the host's immune system to 
develop into tumours. The ability of cancer cells to avoid immune destruction is 
recognised as one of the hallmarks of cancer (98). Immune escape by tumour cells, a 
process termed immunoediting, can be achieved by lack of recognition and sensitivity 
to immune effector mechanisms and induction of immune suppression (100).  
In 2001 it was discovered that apart from preventing tumour formation, the presence of 
an active immune system also shapes tumour immunogenicity (102). Proliferation and 
mutation of tumour cells with tumour progression also reduce tumour immunogenicity 




immunoediting resulted in a decrease of neoantigens from early to advanced stage, 
eliminating immunoreactive subclones and selecting immune-privileged subclones 
(109). Several studies have also shown defects in the antigen-presenting machinery 
and antigen processing of cancer cells, such as loss or downregulation of MHC class I 
(100). Lack of sensitivity to the immune system's cytotoxic effect can also be achieved 
by resistance to apoptosis, either by overexpression of anti-apoptotic receptors (BCL-
2) or activation of pro-oncogenic transcription factors (STAT3) (100). 
Cancer cells induce immune suppression by active secretion of immunosuppressive 
cytokines, paralysing tumour infiltrating CTLs and NK cells and recruiting 
immunosuppressive inflammatory cells (Tregs, macrophages and myeloid-derived 
suppressor cells). These immunosuppressive cytokines also upregulate co-inhibitory 
receptors on T cells, suppressing T cell activity. Ligands of co-inhibitory receptors, 
such as PD-L1, is also expressed on tumour cells in many types of cancers (98, 110, 
111).  
1.8 Prognostic and predictive tumour markers 
In the era of precision oncology, specific tumour gene or protein information is 
analysed to tailor the patient's treatment based on their predicted response or disease 
risk. This enables clinicians to give each patient the most optimal and effective 
treatment regimen to improve survival and avoid non-beneficial overtreatment and 
toxicity for all non-responders. A key concept of precision medicine is the use of 
biomarkers, defined b  the National Cancer  nstitute as “a biological molecule found 
in blood, other body fluids or tissues that is a sign of a normal or abnormal process, or 
of a condition or disease” (112). These biomarkers are categorised as prognostic or 
predictive, or both. Predictive markers identify patients that most likely benefit from a 
particular treatment. On the other hand, a prognostic marker gives information on 
patient outcome/disease course and categorises patients into different risk groups. This 
could also influence treatment choice. A patient with a poor prognosis might benefit 
from a more intensified chemotherapy regimen upfront as few make it to second and 
third-line treatment. Carcinoembryonic antigen (CEA), a blood-based biomarker, was 
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the first biomarker implemented for CRC patients. It is recommended to be measured 
preoperatively for prognostic assessment and monitoring of disease recurrence. If 
initially elevated, CEA is also recommended to be monitored at response evaluation 
during palliative chemotherapy for mCRC patients (113), as increasing levels could be 
an indication of treatment resistance. However, a surge in CEA level is observed in 
certain responding patients after initiating chemotherapy treatment (114), and about 
one-third of patients have no elevation of CEA at diagnosis.   
In the era of precision medicine, a major focus has been on developing targeted 
treatment by identifying tumour specific targets or affecting critical tumour signalling 
pathways, thereby avoiding or minimizing the effect on normal cells. The development 
of new cancer treatment is expensive and often benefit a smaller subgroup of patients. 
Therefore, predictive biomarkers are also considered cost-effective. Much effort has 
been made to find prognostic and predictive markers to optimize cancer treatment, but 
so far, remarkably few have entered the clinic. In fact, precision oncology guided by 
cancer genome profiling has so far provided only a modest increase in treatment 
benefit. The estimated proportion of patients who showed benefit from genome-
informed treatment in the US in 2018 was less than 7 % (115). And CRC lags behind: 
systemic treatment options are few compared to other major cancer types (116), and 
each of the “actionable” molecular mar ers is found in only 1-5 % of the cancers 
(117).  
In this thesis, we have focused on tumour molecular biomarkers. Of note, certain 
clinicopathological factors, such as performance status, age, comorbidity, blood test 
(e.g. CEA, leukocytosis, ALP, CRP), sidedness of primary tumour, site and number of 
metastasis, histopathological grading and other features remain important prognostic 
factors. They should be considered in combination and relation to tumour molecular 
markers.  
1.8.1 BRAF/KRAS/NRAS  
Tumour BRAFV600Emut status is a well-validated poor prognostic marker in localised 
(118) as well as mCRC (72) and is recommended to be assessed in the clinical 




mCRC patients have an unexpectedly prolonged survival despite tumour BRAF 
mutational status. This was recently addressed in a study of 395 BRAFmut patients, 
where clinical factors defined three vastly different prognostic subgroups (120). 
Tumour BRAFmut is also associated with MSI status, and some studies have revealed 
that the poor prognosis of BRAFmut is limited to MSS tumours. However, results are 
conflicting and inconclusive due to the limited number of patients in these subgroup 
analyses (118, 121, 122). Future studies are needed to explore the reason for the 
survival heterogeneity in the BRAFV600Emut subgroup. Studies of rare non-V600 
BRAFmut have revealed distinct clinical subtype with a good prognosis, even 
exceeding the prognosis of BRAFwt patients (73, 75). However, insufficient data is 
currently available to determine the prognostic value of non-V600E BRAFmut due to 
the limited number of patients in these studies. Since BRAFV600Emut generally predicts 
a poor prognosis, patients with a good performance status are recommended an 
intensified chemotherapy regimen in 1st-line palliative treatment (FOLFOXIRI + 
bevacizumab). BRAFmut is considered a predictive marker for BRAF-inhibitors 
(vemurafenib or dabrafenib) in metastatic malignant melanoma patients (123, 124). 
However, results on mCRC patients have been disappointing (125). Recently, 
encouraging data has been published on BRAF-inhibitor treatment combined with 
EGFR-inhibitors for these patients (44). At least a dual-targeted inhibition of the 
MAPK pathway seems needed for the obliteration of the signalling cascade. BRAF-
inhibitor combination treatment is now recommended as 2nd-line treatment for 
BRAFmut cases according to NCCN and Danish national guidelines.  
KRASmut is a common event in CRC. This might explain why it has not been a 
promising marker to identify prognostic subgroups. However, survival rates after 
radical metastatic surgery for mCRC varies according to mutation status. KRASmut 
and especially BRAFmut has been identified as adverse prognostic markers after liver 
surgery (126-128). Following hepatectomy for mCRC patients with available BRAF 
status, 5-year survival was 37 % in BRAFmut vs 67 % for BRAFwt (129). Another 
study reported inferior median survival in BRAFmut (23 months) compared to 42 
months in RASmut and 63 months in double wildtype (130).  Five-year survival after 
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lung surgery in mCRC patients was 0 % for BRAFmut, 44 % for KRASmut and 100 % 
for double wildtype, with corresponding median survival rates of 15 months, 55 
months and 98 months, respectively (131). RASmut and BRAFmut also impair survival 
after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy(132).  
 
Randomised trials have shown that EGFR inhibitors adds no survival benefit in 
patients with tumour KRASmut status and later NRASmut (133, 134), as these 
mutations occur downstream of the EGFR signalling pathway. The primary tumour 
site might also implement the treatment effect, as studies have shown improved benefit 
in patients with left-sided RAS wildtype tumour (135). There is reason to believe that 
other mutations in the RAS-signalling pathway also negatively predict the EGFR 
inhibitors effect. Recent studies have reported BRAFmut as a potential predictive 
marker in this setting (136, 137). Nevertheless, since BRAFmut is a less frequent 
mutation, associated with poor prognosis and inadequate chemotherapy response, 
predictive assessment is challenging (138, 139). Randomised trials are lacking and will 
probably not be conducted in the future due to new upcoming treatment options for 
these patients (BRAF inhibitors and ICIs for MSI). Taken together, RAS and BRAF 
mutation accounts for >50 % of mCRC patients who then are not eligible for EGFR 
inhibitor treatment. Due to RAS proteins' central role in intracellular signalling and the 
high frequency of RASmut in CRC and other cancers, targeted treatment of RAS or 
RAS effector pathway seems promising. The development of RAS inhibitors has been 
challenging and ongoing for more than 40 years. It also needs to be constructed 
specifically for the mutated protein of interest to minimise the effect on normal RAS 
signalling. A specific inhibitor of KRAS G12C (sotorasib) has recently shown 
promising results in a phase II trial of previously treated metastatic non-small cell lung 
cancer with this specific mutation (140). The potential effect of KRAS G12C inhibitor 
for mCRC patients is currently under investigation. Still, this specific KRASmut is a 






The good prognostic effect of tumour MSI status in localised CRC has been 
thoroughly demonstrated in several studies, including randomised trials and meta-
analyses (142, 143). In mCRC, on the contrary, MSI has been associated with an 
adverse prognosis in most studies (121, 122, 144). MSI leads to the accumulation of 
mutation-associated neoantigens on tumour cells, registered as foreign by the immune 
system, thereby activating the immune cascade resulting in increased TILs. This is 
believed to explain why MSI is recognised as a good prognostic marker in localised 
CRC (145). The cause of poor prognosis of MSI in mCRC is not known, and the 
association to and prognostic role of TILs in mCRC MSI tumours is not established. 
Previous studies have found MSI CRC enriched in mutations of critical immune-
modulating pathways and antigen-presenting machinery, including MHC class I and 
B2M, as well as upregulation of checkpoint inhibitors (146-149). This has also been 
demonstrated in studies of Lynch syndrome patients (150). This immunoediting 
process allows immune escape despite the highly immune infiltrated tumour 
environment and is believed to be one of the reasons why MSI tumours are not 
eliminated by the activated immune system itself. Transcriptome analysis revealed that 
MSI CRC tumours display upregulation of checkpoint inhibitors that exhausts 
cytotoxic T cells and predicts a poor outcome, independent of tumour stage (148). 
They also reported an adverse prognosis of PDL-1 expression and immune checkpoint 
metagenes in an independent cohort of 28 MSI mCRC patients. MSI tumours have 
also been enriched in resistance mechanism to interferons secreted by activated T 
cells, such as Jak and Stat mutations, and could be a potential immune escape 
mechanism (151). Other factors have been proposed to explain the stage-dependent 
heterogeneous prognosis of MSI in CRC, such as the observed lower frequency of 
liver metastases and higher frequency of peritoneal metastases (122, 152) and right-
sided tumour (153). Tumour MSI status is frequently cooccurring with BRAFmut (121, 
122) in sporadic CRC, and the independent prognostic effect of these tumour 
molecular markers are not clarified.  
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MSI is recognised as a predictive marker for immunotherapy with ICIs in mCRC (46). 
The treatment effect is thought to be due to increased infiltration of immune cells in 
these tumours. However, not all patients respond clinically, as around 30 % of patients 
had direct progression on pembrolizumab in the recent 1st-line randomised trial (48). 
Assessment of TILs has been suggested as a potential predictive marker for these 
patients (154), but so far, studies are lacking. A higher ORR was observed in a small 
study of 85 MSI patients with high TILs (155). No studies have yet explored if TILs 
are predictive in the MSS subgroup of mCRC. A minor study of localised CRC that 
underwent neoadjuvant ICIs demonstrated a significantly higher tumour density of 
CD8/PD-L1 lymphocytes in responders of the MSS subgroup.  
1.8.3 HER2 
HER2 overexpression is a rare event in CRC, and the prognostic effect is not clarified 
(82, 83), although the presence of high-level amplifications of at least one gene 
(including HER2) was associated with poor survival among stage I-III MSS tumours 
(156). Studies suggest that HER2 overexpression is predictive of resistance to EGFR 
inhibitors (117). In recent phase II trials, encouraging data on HER2 targeted treatment 
has been published for HER2 positive KRAS wildtype mCRC patients. In heavily 
pretreated patients in the HERACLES II trial, 30 % ORR was observed with dual 
HER2/EGFR inhibitor (lapatinib) in combination with HER2 antibody (trastuzumab) 
(157). In the basket study Mypathway, 40 % ORR was observed with dual anti-HER2 
antibody treatment (trastuzumab + pertuzumab) (158).  
As for HER2 overexpression, the prognostic effect of HER2 mutation in CRC is 
uncertain (85). Preclinical studies suggest resistance to EGFR inhibitors with HER2 
mutations(117). Monotherapy with anti-HER2 antibodies have so far not proven 
effective, but dual inhibition of HER2 signalling might be promising (117). Studies of 
HER2 inhibitors (neratinib) in mCRC patients with tumour HER2 mutations or 






Tumour CDX2 expression is downregulated in a subset of CRC patients, and loss of 
CDX2 expression has been associated with poor prognosis (91, 159-161). It has also 
been associated with other poor prognostic markers in mCRC, such as poor tumour 
differentiation, right-sided primary tumour, BRAFmut and MSI (90, 91, 162). No 
studies have fully explored if these associations confound the poor prognosis. It has 
also been associated with the poor prognostic subgroups CMS 1 and CMS 4 (91, 92, 
163). CDX2 loss was reported as a negative prognostic marker for mCRC patients 
undergoing curative liver metastasectomy, indicating CDX2 as a potential biomarker 
to be assessed before surgery to identify patients with limited benefit (164). However, 
this study did not assess KRAS or BRAF mutation status, identified as negative 
predictive markers for liver metastasectomy patients (126, 129, 165). 
In contrast to MSI, CDX2 loss has been reported as a potential predictive marker for 
adjuvant chemotherapy benefit in stage II and III CRC (91, 159). These data are 
limited to retrospective analyses and small sample sizes. In vitro drug screening and 
gene expression analyses has shown higher responses in CDX2 negative cell lines 
(91). However, the difference observed with 5-FU and oxaliplatin, used for adjuvant 
treatment, did not reach significance. Retrospective studies of smaller mCRC cohorts 
have not found tumour CDX2 assessment predictive for chemotherapy effect (91, 161, 
164). Due to the potential predictive and prognostic value of CDX2 loss in CRC, 
determining the prevalence and survival effect in unselected population-based cohorts 
of mCRC patients is warranted. 
1.8.5 Tumor infiltrating lymphocytes and macrophages 
Dense infiltration of TILs is associated with a favourable prognosis in several types of 
cancer (103). But consensus on methods and threshold to define high tumour 
immunogenicity is lacking. In localised colorectal cancer (CRC), the Immunoscore® 
has been developed to standardise tumour immune infiltration analyses for clinical 
implementation (166). This is a combined score of CD3 and CD8 positive T-
lymphocytes at the tumour centre and invasive margin, evaluated on whole tissue 
sections. It has been internationally validated as a prognostic marker in localised 
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colorectal cancer, even superior to the TNM staging system in such cancers (145). The 
prognostic effect of TILs has also been reported in studies of CRC tumour 
centre/tissue microarray (167-169). In a recent metanalysis, combined effect models 
were similar regardless of whether immune cells assessed intratumorally or at the 
invasive margin (170). In the clinic, whole-tissue sections are not always available. A 
substantial group of mCRC patients only have small biopsies taken for diagnostic 
purposes and is not emitted for primary tumour surgery if no clinical benefit of this 
procedure is expected. Prognostic assessment of TILs in studies of central 
tumour/TMA is therefore of clinical importance. Despite several studies in localised 
CRC, the prognostic impact of TILs in the primary tumour of patients with metastatic 
CRC (mCRC) is not established. Most previous reports have been performed on 
metastases of small and highly selected patient cohorts after secondary metastatic 
surgery (171-173), and validation in population-based mCRC cohorts are warranted.  
The observed response of ICIs in MSI tumours is believed to be due to higher 
immunogenicity in these tumours. However, far from all patients with MSI CRC 
respond to ICIs. An intensive effort is currently being made to find a more specific and 
sensitive predive marker for ICIs response. It is believed that the antitumour effect of 
ICIs is achieved by removing the negative regulation of the pre-existing tumour 
immune microenvironment, and assessment of TILs has therefore been suggested as a 
potential predictive marker (105, 174), although studies are lacking. Studies of lung 
and melanoma cancer patients have shown higher tumour density of CD8+PD-1+ 
lymphocytes in responding patients (175, 176). In a small study of MSI mCRC, high 
TILs predicted better response, OS and PFS to ICIs (155). Future studies are needed to 
determine the predictive effect of TILs on ICIs treatment with consensus on threshold 
and methods to determine high and low TILs. The predictive effect of TILs in the 
generally non-responsive MSS mCRC patients has so far not been reported. 
Interestingly, a small study of neoadjuvant ICIs in localised CRC demonstrated a 
significantly higher tumour density of CD8+ PD-1+ lymphocytes in responding MSS 




TAMs have been associated with poor prognosis in several types of cancer (103). 
Studies of CRC patients have shown contradictory results (178-181), and recent meta-
analyses conclude with a favourable prognosis of tumour infiltrating CD68 
macrophages (103, 170, 182). However, studies on mCRC cohorts are lacking. The 
contradictory results could be due to the contrasting function of the different 
phenotypes. The location of TAMs in tumour tissue could also be essential as studies 
(180, 181) and recent metaanalyses concluded with improved survival with higher 
infiltration at the invasive margin. In contrast, studies of tumour centre infiltration did 
not reach significance (170, 182). Due to the evidence of tumour promoting effects of 
TAMs and macrophages plasticity, the potential of targeting TAMs as an anticancer 
treatment seems promising, and several studies are ongoing (183).  
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2. Aims of the study 
The overall aim of this PhD project was to find new and validate known prognostic 
and predictive tumour molecular markers in a population-based cohort of mCRC 
patients. 
Specific aims of the three papers included in the thesis were: 
I. To determine the frequency and evaluate the prognostic effect of MSI in a 
population-based cohort of mCRC, taking into account known prognostic 
clinicopathological variables, including tumour molecular markers. 
II. To determine the prognostic and predictive effect of CDX2 loss in a 
population-based cohort of mCRC related to clinicopathological variables, 
including tumour differentiation and tumour molecular markers. 
III. To determine the prognostic effect of tumour infiltrating lymphocytes and 
macrophages in a population-based cohort of mCRC and explore the impact 
of immune cell density on prognosis for patients with MSI and BRAF 
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3. Materials and methods 
3.1 Patients 
In this project, we analysed tumour and clinical data from a Scandinavian population-
based cohort of mCRC patients (SPCRC). This cohort was collected by prospective 
registration of all patients with non-resectable mCRC adenocarcinoma referred to the 
oncology units of three university hospitals in Scandinavia from 2003-2006. These 
hospitals received all oncology department referrals of their administrative area. 
Uppsala University Hospital in Sweden serves 280 000 inhabitants, Odense University 
Hospital in Denmark 475 000 inhabitants and Haukeland University Hospital in 
Norway 450 000 inhabitants. Patients not referred to the oncology department was 
later identified via national (Norway and Sweden) and regional (Denmark) cancer 
registries (n=49). The cohort consists of 796 patients and represents a truly unselected 
population-based cohort of all non-resectable mCRC patients in a defined area (Figure 
11). Clinical characteristics, pathological evaluation, blood tests and treatment 
regimens were retrieved from CRF. According to Response Evaluation Criteria in 
Solid Tumours (RECIST), treatment response was evaluated on CT scans after 1st, 2nd, 
3rd and 4th-line chemotherapy. It needs to be mentioned that our cohort initially 
consisted of 798 patients. After publishing our first paper, we discovered that two 
patients included did not receive any systemic treatment, underwent curative surgery 
for metastatic disease and should not ha e met the inclusion criteria’s for our stud . 
Removal of these patients had no impact on our published results. 





3.2 Methods  
3.2.1 Tissue microarray 
Tissue microarray (TMA) of tumour specimens enables high-throughput analysis of 
hundreds of specimens on one glass slide. This method facilitates large-scale studies 
and is both time and cost-effective compared to whole-section tumour analysis. 
Furthermore, TMA enables many tumour spots to be stained simultaneously, under the 
same conditions, time interval and method. In our study cohort, formalin-fixed 
paraffin-embedded (FFPE) tissue blocks were retrieved from primary tumour 
specimen in most cases or from a metastatic lesion (6 cases), and corresponding 
haematoxylin-eosin stained glass slides were examined. TMA generation was 
performed in 460 cases according to the standards used in the Human Protein Atlas 
program (184), with two 1-mm diameter tumour cores extracted per patient. The lack 
of inclusion was generally due to small biopsies or necrotic tissue (n = 239), and a 
proportion was displaced in the archive or had no cancer tissue (n = 97). For patients 
without enough tumour material to generate TMA, we collected sufficient tumour 
material for immunohistochemistry (IHC) analyses for MMR and BRAFV600E in 167 
cases. 
3.2.2 Immunohistochemistry  
IHC is a low cost and well-established method for biomarker research and applied in 
routine clinical diagnostics for most cancer types worldwide. The major advantage of 
IHC is the visualization of the biomarker expression in a morphological and 
subcellular context. In papers I and II, we used IHC to detect MMR and BRAF status, 
using methods and image analysis according to standards within the Human Protein 
Atlas (185). Automated staining was performed, reducing operator variability and 
increasing reproducibility. Visual scoring was assessed by two independent 
pathologists without knowledge of clinicopathological data, and annotation 
discrepancies were re-evaluated to reach a consensus. In paper I, a consensus was 
made between MMR staining interpretation (n = 581) and previous results of MSI 
DNA sequencing in BRAFmut cases (n = 91) (25), further referred to as MSI or MSS. 
Furthermore, a consensus was made between BRAFV600E IHC staining and previous 
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BRAF V600E DNA pyrosequencing results (25), available for 446/591 stained cases. 
In paper III, we were able to add results on MSI DNA sequencing for additional 66 
patients (69), and a final MSI consensus was made for 591 patients. Next-generation 
DNA sequencing of a customised Ampliseq hotspot targeted panel (69) was also 
considered for the final BRAF V600E conclusion in paper III (n = 595). 
3.2.3 Multiplex IHC  
In paper III, we used multiplex IHC to identify tumour infiltrating lymphocytes and 
macrophages with The Vectra 3 intelligent slide analysis system (PerkinElmer/Akoya). 
A multispectral camera obtains images at every ten nanometres of the visible 
spectrum, enabling unmixing of multiplexed staining with up to 7 colours. Both 
chromogenic and fluorescent stains can be analysed with the advantage of 
fluorochromes having a much higher dynamic range. The system is based on 
automated imaging and digital image analysis. After imaging, high-resolution cell 
segmentation is performed with a trainable software algorithm for pattern recognition. 
This automation of image analysis increases throughput and is more objective and 
quantitative compared to visual analysis (186). Furthermore, multiplexing enables the 
study of biological networks and facilitates a deeper analysis of heterogeneity and 
spatial relationships between different proteins in situ. Hence, this method is well 
suited to study the complex network of the immune cells in the tumour 
microenvironment.  
3.2.4 Statistical methods 
To evaluate correlations between the studied biomarkers and clinicopathological 
characteristics, exact chi-square test and multiple binary logistic regression were used 
for group comparisons between dichotomous variables, such as BRAF, MSI and CDX2 
status. Immune cell markers were analysed as a continuous variable, with non-
parametric Mann-Whitney U-test and Spearman's rank-order correlation. In 
multivariate analysis, linear regression was used with square root-transformed density 




OS was calculated from the date of radiologically confirmed unresectable metastatic 
disease to the date of death and censored if the patient was alive on 4 February 2014. 
PFS was the interval from the date of the first administration of chemotherapy to the 
date of progression (on CT scan) or death and censored if the patient was alive without 
progression on 4 February 2014. The Kaplan-Meier method was used to generate 
survival curves, and the log-rank test was used to compare the curves. Multivariable 
models were developed according to the Cox proportional hazards method, and OS 
and PFS were used as clinical endpoints. Formal interaction tests were integrated into 
the Cox models to assess whether effects were different between subgroups. However, 
results must be interpreted carefully due to the low power of such tests. In the fully 
adjusted Cox multiple regression analyses, we included variables statistically 
significant for survival in our cohort and available prognostic variables recommended 
by Goey et al. (187). All analyses were performed using the statistical software 
program IBM SPSS v25.   
3.3 Ethical considerations 
The prospective collection of a Scandinavian population-based cohort of mCRC 
(SPCRC) was approved by the regional committee for Medical and Health Research 
Ethics – REC West (Norway) (114 03), Regional Ethical Committee Uppsala 
(Sweden) and the Regional Scientific Ethical Committees of Southern Denmark. The 
study was conducted according to the declarations of Helsinki. Patients at the 
oncology department signed a written informed consent to participate in the study. 
Patients with mCRC not referred to the oncology department who died of the disease 
during the inclusion period were later identified through national (Norway and 
Sweden) and regional (Denmark) cancer registries, approved by REC West 
(2009/2052). General biobank approval was granted by REC West (2018/2111). REC 
West also approved the current PhD project on the general biobank (2019/30).  
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3.4 Methodological considerations 
3.4.1 Tissue microarray 
A major concern with the TMA method is the risk of not detecting possible 
heterogenous expression of tumour biomarkers. Tumour formation and progression is 
an evolutionary process, and subclones with survival advantage will be selected for 
further growth and division (188). Therefore, a small histospot from one particular part 
of a tumour might not represent the majority of tumour tissue. However, large-scale 
studies generally compensate for sampling errors. In the generation of TMA in our 
cohort, two tumour spots were taken from each patient to reduce the potential bias of 
tumour heterogeneity. Although rare, previous studies have raised concern about 
tumour heterogeneity of MMR staining (189, 190). However, we recently reported 
compliance between TMA and whole-tissue section staining of MMR and CDX2 in a 
cohort of early-stage CRC (191).  
Another concern might be that the metastatic site has a different molecular profile than 
the primary tumour. In the generation of TMA, most spots were taken from the 
primary tumour and not from the metastases. However, for CRC, there seems to be a 
good correlation between driver gene mutations in the primary and the metastatic site 
(127). Studies have shown that the dominant clone of metastatic cells can change 
genotype/phenotype from the start of 1st-line chemotherapy to the last line of 
treatment, especially for RAS mutation status. The emergence of treatment-induced 
KRASmut with acquired resistance to anti-EGFR treatment has been demonstrated in 
several studies of mCRC (192, 193). Heterogeneity between primary tumour and 
metastases is difficult to assess. It is generally not feasible to biopsy all metastatic 
lesions of a patient, as many patients harbour multiple metastases in multiple organs.  
Another problem with the TMA method is the selection bias of omitting cases without 
sufficient tumour tissue. This could be due to small biopsies or rectal cases with 
massive necrosis after preoperative chemoradiation. This bias is, however, present for 
all studies of tumour tissue biomarkers. Our research group have previously shown 




older, had worse performance status, more metastatic sites, primary tumour less often 
resected, more often abnormal baseline prognostic blood tests, received less 
chemotherapy and had an inferior prognosis compared to patients with TMA available 
(25). In paper I, we included additional patients outside the TMA cohort for IHC 
analyses of MMR proteins and BRAFV600E mutation. However, results of CDX2 
staining and tumour immune markers studied in paper II and III are only based on 
patients with TMA generated.  
The failure to detect tumour heterogeneity and tissue selection bias might be overcome 
by the use of liquid biopsies. This is a steadily evolving, minimally invasive method, 
detecting circulating tumour DNA (ctDNA) shed into the bloodstream by tumour cells. 
Recent studies report good concordance between driver gene mutations detected in 
tissue and blood (193, 194). Detection of mutations from ctDNA could also enable 
monitoring tumour evolution over time (195, 196). There is a risk of false-negative 
results with non-shedding tumours or low tumour burden, and standardisation of 
methods and large prospective studies are needed (195, 196). This method will only 
apply to mutations detectable by DNA-based methods, and therefore, for instance, not 
applicable for studies of immune cells in the tumour microenvironment. 
Despite heterogeneity concerns, TMA enables large scale studies with high throughput 
analyses that reduce sampling bias and increase statistical power. For these reasons, 
TMA is widely used and considered a highly efficient method to discover and validate 
prognostic and predictive biomarkers.  
3.4.2 Immunohistochemistry 
The IHC method contains various steps, and many factors could impact the results. 
Even preanalytical factors, such as neoadjuvant radiotherapy for rectal cancer (197), 
the time spent from tissue resection to formalin fixation and length of formalin fixation 
(198), could give rise to different degrees of epitope degradation. The use of archived 
tissue specimens could also affect the staining, as some epitopes might be less stable 
than others. Still, FFPE tumour tissue is believed to retain its antigenicity for several 
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decades in proper storage conditions. With the use of high-quality antibodies, the 
staining is retained for most markers over time.  
Antigen retrieval after formalin-fixation can be applied by many different methods, a 
potential cause of variable results between labs. Furthermore, antibody specificity and 
sensitivity may vary from different vendors. Commercial antibodies are often poorly 
validated (199), although some companies provide higher quality antibodies with more 
data on validation (e.g. XP range from Cell Signaling Technology). It is important to 
optimise antibody concentration for each particular antibody of interest. A short 
dynamic range will not differentiate between weakly stained tumours in low antibody 
concentration, and a high antibody concentration will lead to overstaining of the highly 
stained tumours. The method of detection and signal amplification is another crucial 
step. For detection, we used chromogen diaminobenzidine (DAB), which is well 
validated and most frequently used. Chromogen detection is based on light absorption, 
leading to a limited dynamic range, which means that there is no linear relationship 
between staining and intensity and the amount of biomarker detected (Beer lambert 
law). In comparison, emission-based fluorochrome detection, utilised for immune cell 
detection in paper III, has the advantage of a higher dynamic range. 
3.4.3 Staining interpretation and threshold determination for biomarkers  
Visual semi-quantitative assessment is the established standard in IHC but is prone to 
bias of interobserver variability. Firstly, the localization of the antigen of interest needs 
to be determined, as proteins have different functions in different subcellular 
localization. Staining is then scored according to levels of intensity and fraction of 
positive cells or reported as multiplication (H-score) (200) or summation (Allred 
score) (201) between the two, making it difficult to compare results from different 
labs. Furthermore, different thresholds are used to identify positive and negative 
staining, and in the early stage of biomarker research, there is generally no consensus 
on how to interpret the staining results. Staining intensity is especially prone to 
interpretation bias by using different fixatives, storage time of unstained sections and 




For this reason, we chose only to evaluate the fraction of CDX2 stained cells when 
interpreting CDX2 staining in paper II. Furthermore, no consensus on the staining 
interpretation of CDX2 as a prognostic marker in CRC has been established. The 
threshold for negative staining was set to nuclear fraction < 10 % based on the 
distribution of expression across our cohort, with most patients expressing a high 
nuclear fraction.  
Determination of dMMR by IHC is a widely used method implemented in the clinical 
diagnostics of CRC. However, no well-studied, evidence-based threshold for normal 
MMR expression has been established (197). We defined the threshold for loss of 
MMR proteins as complete loss of nuclear staining, as applied by the College of 
American Pathologists POET report (203). Patients were further categorised as dMMR 
if staining was absent for MLH1 + PMS2, PMS2 alone, MSH2 + MSH6 or MSH6 
alone. For BRAFV600E, the cytoplasmic staining was qualitatively scored as positive 
(mutated) or negative (wildtype) as applied by previous CRC studies (204, 205). With 
the applied fluorescent multiplex IHC method for staining tumour immune cells in 
paper III, the scoring was much more objective and quantitative due to automated 
image analysis. This method is more standardised and robust (186), with higher 
resolution than IHC with chromogen staining. Evaluating the staining results as a 
continuous density variable could also enable the detection of additional clinical 
subgroups. Nevertheless, to be implemented as a prognostic or predictive marker, it is 
advantageous to apply a threshold to divide patients into different risk groups. There is 
no consensus on a threshold for high and low tumour immune cell infiltration in 
central tumour/TMA studies. Several studies have shown that the median value is 
associated with prognosis in CRC (169, 173, 206, 207). This value will, however, 
differ from each patient cohort studied and is not an objective measure. Hence, we 
chose to report survival prediction as both continuous variable and median value.  
3.4.4 Validation of IHC results 
Several studies have shown similar sensitivity and specificity of MMR detection by 
IHC and MSI detection by DNA based assays utilizing polymerase chain reaction 
(PCR). Both tests are readily used in clinical diagnostics (197). However, around 5 % 
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of cases with MSI have normal staining of MMR proteins (203). In paper I, we 
compared the staining results of MMR and previously sequenced MSI available for 
most cases with BRAFmut. As most of our dMMR/MSI cases also harboured 
BRAFmut (87 %), we were able to validate the IHC results for the majority of dMMR 
cases. In paper III, we were able to add MSI PCR results on additional patients, 
enabling validation of IHC results for 157/581 cases with final staining interpretation. 
Only one patient had inconsistent results between these two methods, supporting that 
the methods are comparable and sufficient to detect dMMR/MSI. In clinical practice, 
tumour BRAF mutation status has routinely been analysed by DNA-based PCR 
methods. However, these tests are not always available as they require molecular 
pathology expertise in routine labs. Previous studies utilising VE1 antibody for 
detection of BRAFV600E have shown variable sensitivity and specificity (204, 205, 
208). In paper I, we compared our IHC BRAFV600E interpretation with previous DNA 
pyrosequencing for BRAF V600 on the TMA cohort, with results available for 446/591 
stained cases. This resulted in six inconsistent results. In paper III, we had the 
opportunity to include results on BRAF mutation from targeted sequencing of a 
customised Ampliseq hotspot panel on the TMA cohort, with results available for 447 
patients. A consensus of all three methodological results was made, further securing 
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4. Summary of results 
4.1 Paper I 
Recent encouraging treatment options for patients with mCRC include ICIs and BRAF 
inhibitor combination treatment provided for MSI and BRAFmut cases, respectively. 
Assessment of prevalence and prognostic impact of these biomarkers in a general 
population of mCRC is therefore warranted. Our cohort of mCRC patients identified 7 
% MSI and 20 % BRAFmut cases, around twice as high as previous trial publications. 
MSI and BRAFmut were highly correlated. Most of our MSI cases were BRAFmut (87 
%) with a median age of 75 years, in contrast to patients included in recent ICIs trials, 
with 0-25 % BRAFmut cases and a median age of 46-63 years. MSI was also 
associated with right-sided primary tumour, female sex and poor tumour 
differentiation.  
MSI indicated poor survival in mCRC, with median OS of 6 vs 11 months for MSI vs 
MSS cases (p=0.004). We confirmed the negative prognosis of tumour BRAFmut 
status with 7 vs 12 months median OS in BRAFmut vs BRAFwt cases, respectively (p 
< 0.001). In patients treated with chemotherapy, both MSI and BRAFmut were 
independent poor predictors for OS and PFS in multivariate regression analyses. MSI 
cases had limited benefit of 1st-line chemotherapy, with an ORR of 5 % compared to 
40 % in the MSS group, and few made it to 2nd-line treatment. Subgroup survival 
analyses revealed that the prognostic effect of MSI only reached significance in the 
BRAFwt subgroup, and the poor prognosis of BRAFmut was only observed in MSS 
cases.  
4.2 Paper II 
CDX2 is an important intestine-specific transcription factor and TSG, and recent 
studies indicate tumour CDX2 staining as a new potential predictive marker for 
adjuvant chemotherapy in CRC. The prognostic and predictive effect in mCRC cohorts 
has not been thoroughly investigated. In our unselected population-based cohort of 
mCRC patients, CDX2 loss was identified in 19 % of patients and indicated a poor 




vs 24 months in cases with tumour CDX2 loss vs expressed (p < 0.001). CDX2 loss 
was associated with other poor prognostic markers such as MSI, BRAFmut and poor 
tumour differentiation.   
CDX2 loss was also confirmed as an independent negative prognostic marker for OS 
and PFS in multivariate regression analyses. Expression of CDX2 identified subgroups 
of BRAFmut and KRASmut cases with a much better prognosis (median OS 21 
months), comparable to wildtype patients (27 months). Loss of CDX2 expression 
identified subgroups of BRAFmut and KRASmut cases with poor prognosis (median 
OS 8 and 11 months, respectively).  
Immediate progression on 1st-line combination chemotherapy was seen in 35 % of 
patients with tumour CDX2 loss, compared to 10 % with tumour CDX2 expressed (p = 
0.003). After 1st-line combination chemotherapy, median PFS was four vs nine months 
in cases with CDX2 loss vs expressed (p = 0.001). Furthermore, patients with tumour 
CDX2 loss received less 2nd-line treatment (23 % vs 39 %, p=0.006) and secondary 
surgery (1 % vs 9 %, p = 0.019) compared to patients with tumour CDX2 expression. 
Patients with tumour CDX2 loss had no survival benefit of doublet chemotherapy vs 
monotherapy in 1st-line treatment. 
4.3 Paper III 
Due to lack of knowledge of the impact of tumour immunogenicity in mCRC, we 
explored the prognostic effect of immune cell infiltration in the primary tumour of 
metastatic colorectal cancer patients using fluorescent multiplexing IHC panel 
including antibodies detecting CD3 and CD8 lymphocytes and CD68 macrophages. 
We found that tumour immune cell infiltration was associated with MSI status. 
However, the distribution was heterogenous, with two-thirds of MSI and one-fourth of 
MSS cases displaying the highest quartile infiltration of CD8 lymphocytes.  
In patients treated with chemotherapy, high tumour infiltration of CD3 lymphocytes 
was associated with a favourable prognosis, with a median OS of 20 vs 16 months 
(HR: 0.76, p=0.025). This was of particular importance on long-term survival with a 
three-year OS of 27 % vs 13 %, respectively. Tumour infiltrating CD3 lymphocytes 
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was an independent positive prognostic marker for OS, corrected for other important 
prognostic markers such as BRAFmut, MSI and CDX2 status. The poor prognosis of 
MSI, BRAFmut and CDX2 loss was independent of tumour immune infiltration. 
Subgroup analysis revealed that CD3 TILs was only prognostic in the major groups of 
patients with tumour MSS, BRAFwt and CDX2 expression.  
For CD68 high vs low cases, median OS was 23 vs 15 months (HR: 0.69, p=0.003) 
with a three-year OS of 28 % vs 12 %. Tumour infiltration of CD68 macrophages was 
an independent good prognostic marker when dichotomised by the median value but 
did not reach significance when assessed as a continuous density variable. Patients 
with a high combined tumour density of CD3 and CD68 cells had a median OS of 25 
months compared to 15 months in patients with low infiltration of CD3 and CD68 
cells (p=0.002). 
Patients with low infiltration of CD3 lymphocytes had no survival benefit of 
oxaliplatin-based combination chemotherapy compared to 5-FU monotherapy in 1st-











5.1 Discussion of results 
5.1.1 Prevalence of adverse prognostic biomarkers in population-based cohorts 
Most previous studies of prognostic and predictive biomarkers in mCRC are based on 
selected and better prognostic subgroups of patients included in clinical trials or 
referral hospital cohorts (49). We, therefore, hypothesize that the incidence of poor 
prognostic markers in population-based cohorts will be higher. Indeed, this is what we 
showed in paper I, with around twice as high incidence of both MSI and BRAFmut 
cases as compared to previous studies (121, 209, 210). We believe this is due to the 
unselected nature of our cohort, with many elderly patients and patients with poor 
performance status generally excluded from clinical trials. In fact, the same frequency 
of BRAFmut was reported in a recent Nordic phase II trial of elderly vulnerable 
patients with mCRC (211). Due to the poor prognosis related to these biomarkers with 
new upcoming encouraging treatment options, our study emphasises the importance of 
assessing these tumour biomarkers for all mCRC patients.  
5.1.2 MSI 
In our population-based mCRC cohort, MSI is a poor prognostic marker, in 
accordance with other previous publications (121, 209, 210). Our results were later 
validated in a large cohort of 281 dMMR cases (144). In early-stage CRC, MSI is 
associated with a good prognosis, and we attempted to explore potential reasons for 
this heterogeneous prognosis across tumour stage. We found that MSI was highly 
associated with BRAFmut status and CDX2 loss. This could not solely explain the 
poor prognosis, as MSI was an independent poor prognostic marker for survival. MSI 
was also a poor prognostic marker in BRAFwt cases, although we had few patients in 
this subgroup analysis. In paper III, we demonstrated that, as for early-stage, MSI is 
highly associated with TILs. In studies of early-stage CRC, the good prognosis of MSI 
has been addressed to this fact (145). But although CD3 TILs is an independent good 
prognostic marker for survival in our chemotherapy-treated patients, MSI is still an 




due to accumulating immune escape mechanism with tumour progression. Previous 
studies of MSI CRC tumours have revealed evidence of tumour immune evasion, such 
as enrichment in mutations of immune-modulating pathways and antigen-presenting 
machinery and upregulation of checkpoint inhibitors compared to MSS tumours(146-
150). Future studies should evaluate if accumulating immune evasion mechanisms 
with tumour progression could explain the heterogeneous prognosis of MSI across 
tumour stage. 
MSI is recently implemented as a predictive marker of ICIs effect, as FDA and 
recently EMA have approved ICIs as 1st-line treatment in MSI mCRC patients. In our 
population-based cohort, MSI patients have a particularly poor prognosis with an 
inferior response to standard chemotherapy compared to MSS patients. The obtained 5 
% ORR after 1st-line chemotherapy in our cohort is in great contrast to 44 % ORR 
obtained in recent 1st-line ICIs trials (48), with 83 % ongoing responses at 24 months. 
This could be particularly important for MSI patients with potentially resectable 
disease, needing the best response, which our study shows are not achieved by regular 
chemotherapy. We also observed that a substantial amount of MSI patients never made 
it to 2nd-line treatment. This further supports the use of ICIs in early lines, preferably 
in 1-st line, to ensure that most patients with MSI will have the opportunity to receive 
ICIs.  
The marked difference between our MSI patients and patients included in recent ICIs 
trials should be considered when transferring trial results to the general population (46-
48, 212). Most of our MSI cases were BRAFmut (87 %), in strong contrast to patients 
included in recent ICIs trials (0-25 %). MSI was more often identified in elderly 
patients, with a median age of 75 years, compared to 46-63 years in ICIs trials. 
Although no difference in response and survival has been observed according to BRAF 
status in these trials, additional data on ICIs in the more prevalent BRAFmut MSI 
cases in the general population is needed. Elderly patients are generally not included in 
clinical trials, and studies on efficacy and side-effects of ICIs in elderly mCRC are 
clearly warranted.  
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Despite the impressive response of ICIs in the poor prognostic subgroup of MSI 
mCRC patients, around 30 % of these patients have immediate disease progression on 
this treatment, and assessment of TILs have been proposed as a potential predictive 
marker in this setting (105, 174). Our study demonstrates that although TILs are highly 
associated with MSI status, the distribution is somewhat heterogeneous between the 
groups. Two-thirds of MSI cases and one-fourth of MSS cases displayed the highest 
percentile group of CD8 lymphocyte infiltration and might be potential subgroups of 
ICIs effect. This finding further stresses the need for future ICIs studies exploring the 
predictive effect of TILs in both MSI and MSS subgroups.  
5.1.3 BRAF mutations 
Tumour BRAFmut is a well-validated and widely used poor prognostic biomarker in 
the clinical assessment of mCRC patients (72, 119). However, in the clinical setting, 
we observe a heterogenous prognosis of these patients despite detected mutation. 
BRAFmut is an independent poor prognostic marker for OS in our population-based 
cohort and significantly predicts poor prognosis in MSS patients. BRAFmut and MSI 
status is highly correlated, and the poor prognostic effect of MSI did not reach 
significance in BRAFmut cases, although the limited number of cases affects statistical 
power. CDX2 expression, on the other hand, identified a subgroup among BRAFmut 
cases with a good prognosis, with survival comparable to BRAFwt. BRAFmut and 
promoter methylation induced CDX2 loss is often observed in serrated tumours 
developed within the CIMP pathway (65), and a synergistic oncogenic activity 
between CDX2 loss and BRAFmut has been observed in these tumours (213, 214). 
Serrated tumours have been associated with poor prognosis and can be used to stratify 
patients with BRAFmut tumours (63, 215). We believe that CDX2 status, at least in 
part, could explain the observed heterogeneous prognosis of BRAFmut patients, and 
our findings are supported by a study of 155 BRAFmut mCRC (216). Furthermore, 
CDX2 loss has also been shown to identify a particular poor subgroup among 
BRAFmut in stage I-III CRC (91). As BRAF inhibitor combination treatment is 






Loss of tumour CDX2 expression has been consistently observed in a subset of CRC 
with poor prognosis and is proposed as an emerging prognostic and predictive 
biomarker in CRC. Nevertheless, studies of consequences in mCRC cohorts are 
warranted. Loss of CDX2 expression has also been associated with other poor 
prognostic markers in mCRC, such as BRAFmut, MSI, right-sided primary tumour and 
poor tumour differentiation. To our knowledge, no previous studies have fully 
explored if these associations could confound the negative prognostic effect of CDX2 
loss in mCRC. In paper II, we report CDX2 loss as an important independent negative 
prognostic marker in mCRC, corrected for these associated prognostic markers. With 
the feasibility and low cost of this method, already implemented in the clinical 
diagnostics for other purposes, we believe its potential as a new prognostic biomarker 
for mCRC patients should be further investigated in larger cohorts.  
As for BRAFmut, we also demonstrate that CDX2 loss defines a small subgroup of 
KRASmut patients with a poor prognosis. Although, few cases in our analysis preclude 
a firm conclusion. Both BRAFmut and KRASmut have been associated with poor 
prognosis after metastasectomy (126, 131) and may be factors to consider before 
possible metastatic surgery in patients with very advanced disease. We believe that 
CDX2 status also could add important prognostic information prior to surgery when 
considering treatment strategies for these patients. A recent study reported CDX2 loss 
as a poor prognostic marker after liver metastasectomy, but this study did not correct 
for KRAS or BRAF status (164). Our study indicates that CDX2 loss is a negative 
prognostic marker for these patients regardless of mutational status. However, as 
CDX2 loss affects a smaller group of mCRC patients, few cases were available in our 
subgroup analyses, particularly in cases with KRASmut and CDX2 loss, and larger 
studies are needed to verify our results.  
Recent retrospective cohort studies suggest CDX2 loss as a potential predictive marker 
for adjuvant chemotherapy benefit in stage II-III CRC (91, 159). However, no 
predictive value for chemotherapy treatment response was observed in a series of 
mCRC patients (91) or in a cohort of patients that underwent liver metastasectomy 
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(164). In our population-based cohort, patients with tumour CDX2 loss had worse PFS 
and response to 1st-line chemotherapy, and our results are supported by a previous 
study (161). Furthermore, few patients made it to 2nd-line treatment and secondary 
metastasis surgery. This might indicate that these patients need a different treatment 
regimen than given today. Due to the poor prognosis of tumour BRAFmut status, these 
patients are generally recommended intensified chemotherapy upfront. For patients 
with CDX2 loss, this might not be the best treatment option, as our study indicates that 
these patients have no survival benefit from receiving doublet chemotherapy instead of 
monotherapy. However, few patients were included in these subgroup analyses, and 
more extensive randomised studies are warranted to determine the predictive effect for 
all stage CRC.  
5.1.5 Tumour immune microenvironment 
Prognostic evaluation of TILs and macrophages in the primary tumour of population-
based mCRC cohort adds warranted information to this field, as previous studies are 
mainly based on early-stage or metastases of selected mCRC patients that underwent 
curative surgery. In our chemotherapy-treated series, tumour infiltrating CD3 
lymphocytes was an independent good prognostic marker for OS, with apparently 
greater influence on long-term than median survival. Our finding is supported by a 
previous study of mCRC patients that underwent surgery for primary tumour and 
metastases (179). We could not confirm any prognostic impact of tumour infiltrating 
CD8 in our cohort, in line with two previous studies (179, 217). Prognostic studies 
assessing a combined score of CD3 and CD8 TILs in selected mCRC trial patients are 
conflicting (167, 218). Our study found no significant association with TILs and PFS, 
this has also been demonstrated in a small study of 68 mCRC patients (219).   
Although tumour infiltration of CD3 lymphocytes was associated with OS in our 
cohort, it only reached significance in chemotherapy-treated patients. The effect might 
seem more pronounced in studies of early-stage CRC. Our study also illustrates that 
the prognostic effect might be restricted to the major groups of patients with tumour 
MSS, BRAFwt and CDX2 expression status. However, we had limited cases within the 




mutation of tumour cells reduce tumour immunogenicity and escape from the immune 
response; a process termed immunoediting. Previous studies have shown evidence of 
several immune escape mechanisms during tumour progression, such as upregulation 
of checkpoint inhibitions, tumour-secreted immune-suppressive cytokines and 
exhaustion of cytotoxic T-cells (98, 111).  
As recent studies have suggested that a high Immunoscore® could predict benefit from 
adjuvant chemotherapy in stage III CRC (220, 221), we wanted to investigate the 
survival effect of oxaliplatin-based chemotherapy according to TILs. We found that 
patients with low infiltration of CD3 TILs had no survival benefit of oxaliplatin-based 
chemotherapy compared to 5-FU monotherapy, in contrast to patients with high 
infiltration of CD3 TILs. These results need to be evaluated with caution due to a 
limited number of patients. Oxaliplatin induces immunogenic cell death, which could 
be the reason for the observed inferior response in tumours with low immunogenicity 
(222). Patients with high TILs seem to have a generally better prognosis with 
improved benefit of both oxaliplatin-based chemotherapy and ICIs treatment.   
In our chemotherapy-treated patients, CD68 TAMs was associated with improved 
prognosis when stratified by the median value but did not reach significance when 
analysed as a continuous variable, which might suggest that the prognostic effect is 
less robust. TAMs have generally been associated with poor prognosis in various 
malignancies. In contrast, most studies of CRC report a favourable prognosis. A 
spectrum of different TAMs has been identified, with diverse functions in the tumour 
microenvironment. Two major phenotypes have antagonizing functions on tumour 
cells; M1 with anti-tumour features and M2 with cancer progressive effects, and our 
study could not differentiate between these phenotypes. Future studies should include 
markers to differentiate between these phenotypes to further understand the prognostic 
effect of TAMs in mCRC patients. 
5.2 Strengths  
An important strength of our cohort is the prospective design and the effort to make 
the cohort truly population-based. Due to the health care system in Scandinavia with 
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public health insurance, all patients with mCRC are referred to a regional cancer clinic 
if considered eligible for oncological treatment. In our study, the three attending 
hospitals covered all oncological treatment in their region, and patients not referred 
were later identified via cancer registries, making our cohort truly population-based. 
Other factors that underline the value of our cohort are the detailed and quality 
controlled clinical annotations and long-term survival observation.  
Most studies and current knowledge on tumour biomarkers are based on selected 
patients included in clinical trials or referral hospital cohorts. Our population-based 
study adds important knowledge on tumour biomarkers in the general population of 
mCRC, including the poorly studied subgroups of elderly patients, patients with poor 
performance status and rapidly progressive disease.  
Last but not least, we should mention the strength of the Scandinavian collaborative 
network behind this study. Our study enables the assembly of different research- and 
clinical expertise across the borders and collecting more extensive patient series, 
facilitating cancer research of high standard. Similarities among the countries 
demographics, health care system, cancer incidence and treatment recommendations 
for mCRC patients makes Scandinavian studies reasonable. 
5.3 Limitations 
Population-based studies are important to validate prognostic markers for the general 
cancer patient. However, patients in such cohorts are very heterogeneous regarding 
treatment regimens, comorbidities and other clinical characteristics. This leads to 
many potential confounding factors and smaller subgroups of patients with reduced 
statistical power to detect significant differences. In this non-randomised study, 
patients not given chemotherapy are negatively selected with poor performance status, 
rapidly progressing disease, older age and/or other treatment-limiting comorbidities. 
These patients die rapidly with a median OS of three months and cannot be directly 
compared to the treated group. Therefore, the effect assessment of predictive markers 
is challenging and needs to be confirmed in randomised cohorts. Another challenge 




years ago. Although treatment options for mCRC patients have not changed much in 
the past decade, intensified treatment regimens and metastatic surgery are used more 
often today, leading to an increase in survival for these patients.  
Although the attempt to make this cohort truly population-based, a significant number 
of patients in our cohort did not have enough archived tumour tissue to proceed with 
biomarker analyses. However, this selection bias is present for all studies of tumour 
tissue biomarkers, and these patients belong to the worse prognostic group of mCRC 
(25).  
In biomarker studies, subgroup analyses of patients according to different 
clinicopathological variables are of interest, as biomarkers could have diverse 
prognostic effect in different subgroups. Such analyses are especially prone to bias, as 
various variables could influence the results, and smaller group analyses affect 
statistical power. When exploring the prognostic effect of different biomarkers in 
subgroups of tumour molecular alterations or certain treatment regimens, we had too 
few patients in some groups to draw firm conclusions, and these results need to be 
interpreted with caution.  
  




This study has shown that in the population-based tumour series of mCRC, the 
presence, effect and clinicopathological associations of known tumour biomarkers 
(here MSI and BRAF) differ from results obtained in clinical trials. For CRC, this 
discrepancy is mainly caused by the inclusion of younger and better fit patients in 
clinical trials than in the general cancer population. Our data show that each of the 
three tumour biomarkers studied, MSI, BRAF and CDX2, carry independent 
prognostic information for mCRC. Patients with tumour MSI status or loss of CDX2 
have little effect of chemotherapy in end-stage disease, supporting an earlier and 
different treatment strategy for these subgroups. Tumour CDX2 status identified 
prognostic subgroups of BRAFmut cases that might explain the observed 
heterogeneous prognosis of these patients in the clinical practice. High expression 
levels of immune markers of the tumour microenvironment (CD3 and CD68) are 
prognostic biomarkers for chemotherapy-treated patients with mCRC, with particular 
importance for long-term survival. Despite the high immunogenicity of MSI tumours, 
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7. Future perspectives 
Studies of prognostic biomarkers in population-based cohorts are needed to better 
understand the tumour biology and prognosis of the patients we meet in the daily 
clinic. With new targeted treatments steadily emerging, it is important to know the 
prevalence of these targets and predictive markers in population-based cohorts. We 
experience an increasing demand for real-world data from the regulatory authorities 
when new targeted treatment options are being evaluated for reimbursement by the 
Scandinavian health authorities. Our study on real-world data reports a doubling in 
frequency of MSI and BRAFmut compared to the current estimate. These are 
predictive markers for ICIs and BRAF inhibitor combination treatment, and our 
research is currently being referred to in the ongoing reimbursement evaluation by the 
Norwegian health authorities.  
Due to new encouraging targeted treatment options for these poor prognostic groups of 
patients, our finding underlines the importance of tumour biomarker assessment for all 
mCRC patients. However, since selected patients included in clinical trials are vastly 
different from the general mCRC population, there is a risk that the trial effect will not 
replicate in the clinical practice. In our study, most MSI patients harboured BRAFmut 
and were elderly, in stark contrast to recent ICIs trials. Future studies of ICIs effect in 
the major group of sporadic and elderly MSI patients are clearly warranted as ICIs 
treatment is implemented for the general MSI population. We also report that CDX2 
stratify prognosis in BRAFmut cases, and future BRAF inhibitor combination 
treatment studies should evaluate if CDX2 loss affects response to this treatment.  
Due to our findings and the following verification in a large MSI mCRC cohort, we 
now state that MSI should be acknowledged as a poor prognostic marker in general 
mCRC patients. This knowledge should be adapted in the clinical practice and future 
studies of new prognostic biomarkers in mCRC patients. The short survival and poor 
response to standard chemotherapy in the MSI group indicate that ICIs treatment 
should be given up front, as many patients never reach secondary treatment. This 




patients are treated with curative intent, this could have major implications on survival 
for future patients.  
CDX2 is an emerging prognostic and predictive biomarker in CRC, and our study 
supports this observation and particularly generates new evidence of the independent 
prognostic effect in mCRC. The feasibility, availability and low cost of this method, 
already implemented in the clinical diagnostics for other purposes, further supports its 
potential as a new biomarker for mCRC. However, verification in larger prospective 
and randomised trials is demanded before clinical application. As CDX2 loss defined 
new prognostic subgroups of BRAFmut and KRASmut cases, this is of particular 
interest with potential treatment implications for patients assessed prior to 
metastasectomy and validation of our results in larger cohorts is demanded.  
By combining the predictive biomarker strategy with future pharmacological profiling 
of the patients own tumour cells, grown as 3D patient-derived organoids and screened 
for drug sensitivities (223, 224), we may better identify the patients who will benefit 
targeted treatments. 
Studies of the function and presence of tumour immune cells have led to a broader 
understanding of the impact of the immune system in cancer and the development of 
targeted immunotherapy. Our study provides novel evidence for a prognostic effect of 
tumour immune cell infiltration in mCRC patients. However, standardisation of 
methods and threshold for the identification of high tumour immunogenicity is needed. 
Moreover, the prognostic effect in localised CRC might seem more convincing. Future 
studies should attempt to reveal tumour immune escape mechanisms that could also 
identify new potential targets of immunotherapy in mCRC patients. In future studies of 
our cohort, we plan to evaluate the presence and prognostic effect of different 
checkpoint inhibitors and immunosuppressive Tregs. The observed independent poor 
prognosis of MSI despite high immunogenicity, in contrast to studies of early-stage 
CRC, provides important information in the attempt to reveal the heterogeneous 
prognosis of MSI across tumour stage. To gain a deeper understanding, studies 
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exploring evidence of accumulating immune escape mechanisms with tumour 
progression should be conducted in larger MSI cohorts.  
Continued research on population-based cohorts of mCRC is clearly indicated. 
Patients without enough tumour tissue for analyses have a particularly poor prognosis, 
and new cohorts should aim to include all patients within a defined period for tumour 
biomarker analyses. Therefore, our Scandinavian research group has recently initiated 
a prospective collection of mCRC patients (NewSPCRC) with blood samples to assess 
ctDNA in an assumed tumour heterogeneity dependent manner. Using this strategy, 
we believe we will contribute with new knowledge for this poorly studied patient 
group and a better understanding of the effect of tumour biomarkers for all mCRC 
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